Сòòò½APP

Development and Validation of an Internal Bioinformatic Pipeline for 16S rRNA Amplicon Sequencing

Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Positive Organisms: A Report from the SENTRY Antimicrobial Surveillance Program

Antimicrobial Susceptibility Testing for β-lactam/β-lactamase Inhibitor Combination Agents Against Enterobacterales Isolates Harboring β-lactamase Resistance Genes from North and Latin America: Comparison of VITEK® 2 AES and Broth Microdilution Methods

Rezafungin Activity against Candida and Aspergillus Isolates Causing Invasive Infections in European Medical Centres (2019–2021)

Activity of Cefiderocol and Comparator Agents against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020–2022)

In Vitro Activity of Bacteriophage Cocktail Tested Against Pseudomonas aeruginosa Cystic Fibrosis Isolates

Activity of Cefiderocol and Comparator Agents against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Comparison of In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020–2021)

Activity of Cefiderocol and Comparator Agents against European Enterobacterales, Including Carbapenem-Resistant Isolates, From the SENTRY Antimicrobial Surveillance Program (2020–2022)

In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019–2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets

Cefiderocol In Vitro Activity Against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020–2021)

In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme

In Vitro Activity of Manogepix and Comparators against 610 Infrequently Encountered Yeast and Mould Isolates from the SENTRY Surveillance Program (2017–2022)

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Bloodstream Infections from Europe, Asia, and Latin America (2020–2021)

Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalised with Pneumonia in European Medical Centres (2020–2021)

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Pneumonia in Europe and United States: Results from the SENTRY Program (2019–2021)

Rezafungin Activity against Candidemia isolates collected from European medical centres (2019–2021)

Trends on the Activity of Mould-active Agents Against Aspergillus fumigatus Clinical Isolates With and Without Cyp51 Alterations from Europe and North America (2017–2021)

Impact of the COVID Pandemic in Susceptibility Patterns of Gram- Negative Organisms: A Report from the SENTRY Antimicrobial Surveillance Program

VITEK2 Advanced Expert System β-Lactam Resistance Phenotyping Compared to Whole Genome Sequencing in Enterobacterales Isolates from European Medical Centres

In vitro Activity of Novel Compound RG6006 Against Clinical Isolates of Acinetobacter baumannii-calcoaceticus complex in the Presence of 20% Human Serum

Activity of Cefiderocol and Comparator Agents against US Enterobacterales, Including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Comparison of Cefiderocol and Cefepime-Taniborbactam Activities against Resistant Subgroups of Enterobacterales and Pseudomonas aeruginosa, and Cefiderocol and Sulbactam-Durlobactam Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex

Recent Increase in Fluconazole-Nonsusceptible Candida parapsilosis in a Global Surveillance with the Expansion of the Erg11 Y132F genotype and a Rapid Detection Method to Detect This Alteration

Enterobacter hormaechei Carrying blaNDM Predominates Among Carbapenem-resistant Enterobacter spp. Collected During the SENTRY Antimicrobial Surveillance Program (2016–2021)

Bloodstream Infections in Europe and United States: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021)

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021)

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021)

Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021)

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021)

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021)

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)

In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021)

Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021)

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric Patients from US Medical Centers (2020–2021)

Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/ β-Lactamase Inhibitor Combinations Against These Isolates

In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program

Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020)

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020–2021)

Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other β-Lactam Agents

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type

Activity of Meropenem-Vaborbactam and Comparators Against Enterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)

Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units in US Medical Centers (2010–2019)

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis

Ceftibuten-avibactam (fixed 4 μg/mL), ceftibuten, and ceftazidime-avibactam (fixed 4 μg/mL) broth microdilution quality control ranges using a CLSI M23 (2018) multi-laboratory study design

In vitro activity of manogepix against 1,435 fungal isolates collected worldwide during the SENTRY surveillance program (2020)

Detection of the carbapenem-hydrolyzing CTX-M-15 variant, CTX-M-33, among carbapenem-nonsusceptible Klebsiella pneumoniae isolates from Poland

Comparison of the VITEK2 Advanced Expert System phenotyping and genetic characterization of β-Lactamase Genes for Enterobacterales isolates from North and Latin America

Performance of the VITEK 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales

Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected Worldwide During 2019-2021

Epidemiology of Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in Europe and In Vitro Activity of Gepotidacin (2019-2020)

Endemicity of Pseudomonas aeruginosa Producing IMP-18 and/or VIM-2 Metallo-β-Lactamases from the High-Risk Clone ST111 in Central America

In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021)

Activity of Meropenem-Vaborbactam and Comparators Against European Carbapenem-Resistant Enterobacterales Isolates Producing KPC Carbapenemase (2018-2020)

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific

Activity of Meropenem Combined with the β-Lactamase Inhibitor Xeruborbactam and Comparator Agents Tested Against Challenging Gram-negative Organisms

Activity of Cefiderocol and Comparators against European Enterobacterales including Carbapenem-Resistant Isolates

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020)

Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Activity of Cefiderocol and Comparators against US Enterobacterales, including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)

Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021)

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICU of US Medical Centres in 2021

Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New β-Lactamase Inhibitor Combinations

Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

Dalbavancin Activity against Bacterial Isolates from Pediatric Patients: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program for the United States and Europe (2019-2021)

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries

Rezafungin In vitro Activity against Candida spp. causing Invasive Infections in Hematology/Oncology and Transplant Units Worldwide (2014-2021)

Antimicrobial Activity of New β-lactam/β-lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units

Current Epidemiology and Activity of Gepotidacin and Comparator Agents Against Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in the United States

Intermethod Comparability Analyses of Gepotidacin Antimicrobial Susceptibility Tests Using Over 3,600 Globally-collected Clinical Isolates

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Meropenem-Vaborbactam In Vitro Activities against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers in 2020

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020)

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2019-2020)

Activity of Cefiderocol and Comparators against European Enterobacterales Including Carbapemen-Resistant Isolates

Activity of Cefiderocol and Comparators against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates

Activity of Cefiderocol and Comparators against US Enterobacterales, Including Carbapenem-Resistant Isolates

In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020)

Antimicrobial Activities of Cefepime, Meropenem, Aztreonam, and Piperacillin Combined with Nacubactam against Molecularly Characterized Enterobacterales Collected Worldwide

Prevalence of CC131 and the Emergence of Other Sequence Types among Escherichia coli Isolates Causing Urinary Tract Infections from Asia-Pacific, Europe, and Latin America

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected from Europe during 2019-2020

Activity of KBP-7072, a Novel Aminomethylcycline Antibacterial, and Tetracycline Class Comparators Against 1,057 Bacterial Pathogens Collected Worldwide During 2019

In Vitro Activity of a Novel Aminomethylcycline Antibacterial (KBP-7072) against Clinical Isolates with Molecularly Characterized Tetracycline Resistance Mechanisms

Assessment of Resistance Development to KBP-7072 by Serial-Passage and Single-Step Mutational Selection

Activity of Meropenem-Vaborbactam and Comparators against European Carbapenem-Resistant Enterobacterales Isolates without a Carbapenemase

Activity of Meropenem-Vaborbactam and Comparators against Pseudomonas aeruginosa Isolates from Patients with Pneumonia in European Hospitals

Epidemiology and Molecular Characterization of Linezolid Non-Susceptible Enterococcus spp. Clinical Isolates from the SENTRY Antimicrobial Surveillance Program (2017-2019)

Oritavancin Activity against Gram-Positive Pathogens causing Bone and Joint Infections In European Medical Centres (2015-2019)

Activity of Oritavancin and Comparators against a Contemporary Collection of Enterococcus spp. Clinical Isolates from Europe (2015-2019)

In Vitro Post-Antifungal Effect of Amphotericin B, Fluconazole, and Micafungin against Candida albicans, Candida glabrata, and  Candida parapsilosis

Azole Resistance In Candida glabrata Clinical Isolates from Global Surveillance Is Associated with Efflux Overexpression

Evaluation of Pleuromutilins Resistance Mechanisms Among Surveillance Clinical Isolates: Results from the Worldwide Surveillance Program for Lefamulin in 2019

Five Years of Analysis of the In Vitro Activity of Tedizolid against a Worldwide Collection of Indicated Species Causing Clinical Infections: Results from the Surveillance of Tedizolid Activity and Resistance (STAR) Program

Evaluation of a Protocol for Scalable Preparation of Broth Microdilution Panels for Antifungal Susceptibility Testing Using the EUCAST Reference Method

High Prevalence of Tetracycline Resistance Genes among Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis Clinical Isolates Causing Infections in Europe (2019)

High Prevalence of Tetracycline Resistance Genes among Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis Clinical Isolates Causing Infections in Europe (2019)

wt Kinase Assays

Click the orange "view assays" button to see the full list of available wt kinase assays.

NanoBRET Kinase Assays

Click the orange "view assays" button to see the full list of available NanoBRET assays.

Mutant Kinase Assays

Click the orange "view assays" button to see the full  list of available mutant kinase assays.

Biochemical Binding Assays

Click the orange "view assays" button to see the full  list of available biochemical binding assays.

PDE Assays

Click the orange "view assays" button to see the full  list of available PDE assays. 

Phosphatase Assays

Click the orange "view assays" button to see the full  list of available phosphatase assays.

Epigenetic Assays

Click the orange "view assays" button to see the full  list of available epigenetic assays.

Protease Assays

Click the orange "view assays" button to see the full  list of available protease assays.